期刊
CURRENT CANCER DRUG TARGETS
卷 11, 期 3, 页码 332-337出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156800911794519806
关键词
Antabuse (disulfiram); multidrug resistance; angiogenesis; proteasome; cancer; non-profit drug
类别
资金
- Czech Science Foundation [303/08/P137]
An old drug, Antabuse (disulfiram), used for decades in alcohol aversion therapy, and its metabolite Ditiocarb were shown from 1970s to suppress cancer growth in vivo and even in human patients. The drug targets multidrug resistance, angiogenesis, invasion, and proteasome. Today, there are ongoing clinical trials of Antabuse as an adjuvant therapy against lung cancer and as a monotherapy against cancers metastasizing to liver. The larger clinical trials, if appropriate, will need support from governments and charities to get the generic drug into the clinic as a non-profit drug.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据